{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:36Z","timestamp":1789726296194,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00393-025-01760-7","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:25:10Z","timestamp":1764854710000},"page":"298-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Indirect comparative efficacy and safety of belimumab vs. anifrolumab in systemic lupus erythematosus and lupus nephritis: a\u00a0meta-analysis of randomized trials","Indirekter Vergleich von Wirksamkeit und Sicherheit von Belimumab vs. Anifrolumab bei systemischem Lupus erythematosus und Lupusnephritis: Metaanalyse randomisierter Studien"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4213-1909","authenticated-orcid":false,"given":"Young Ho","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwan Gyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1760_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4078\/jrd.2023.0037","volume":"30","author":"J-Y Han","year":"2023","unstructured":"Han\u00a0J\u2011Y, Cho\u00a0S\u2011K, Sung\u00a0Y\u2011K (2023) Epidemiology of systemic lupus erythematosus in korea. J\u00a0Rheum Dis 30:211\u2013219","journal-title":"J Rheum Dis"},{"key":"1760_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4078\/jrd.2023.0052","volume":"31","author":"R Deniz","year":"2024","unstructured":"Deniz\u00a0R, Hac\u0131murtazao\u011flu-Demir\u00a0G, Karaalio\u011flu\u00a0B et\u00a0al (2024) Lupus nephritis presenting with massive ascites and pleural effusion (pseudo-pseudo Meigs&rsquo; syndrome). J\u00a0Rheum Dis 31:116\u2013119","journal-title":"J Rheum Dis"},{"key":"1760_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4078\/jrd.2023.0065","volume":"31","author":"SM Al-Mayouf","year":"2024","unstructured":"Al-Mayouf\u00a0SM, Hamad\u00a0A, Kaidali\u00a0W, Alhuthil\u00a0R, Alsaleem\u00a0A (2024) Clinical characteristics and prognostic value of autoantibody profile in children with monogenic lupus. J\u00a0Rheum Dis 31:143\u2013150","journal-title":"J Rheum Dis"},{"key":"1760_CR4","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl\u00a0W, Hiepe\u00a0F, Latinis\u00a0KM et\u00a0al (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B\u00a0cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 64:2328\u20132337","journal-title":"Arthritis Rheum"},{"key":"1760_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra\u00a0SV, Guzm\u00e1n\u00a0RM, Gallacher\u00a0AE et\u00a0al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 377:721\u2013731","journal-title":"Lancet"},{"key":"1760_CR6","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie\u00a0R, Petri\u00a0M, Zamani\u00a0O et\u00a0al (2011) A\u00a0phase\u00a0III, randomized, placebo-controlled study of belimumab, a\u00a0monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930","journal-title":"Arthritis Rheum"},{"key":"1760_CR7","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl\u00a0W, Schwarting\u00a0A, Okada\u00a0M et\u00a0al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a\u00a0fifty-two\u2013week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69:1016\u20131027","journal-title":"Arthritis Rheumatol"},{"key":"1760_CR8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et\u00a0al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N\u00a0Engl J Med 383:1117\u20131128","journal-title":"N Engl J Med"},{"key":"1760_CR9","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.4049\/jimmunol.174.5.2499","volume":"174","author":"A Mathian","year":"2005","unstructured":"Mathian\u00a0A, Weinberg\u00a0A, Gallegos\u00a0M, Banchereau\u00a0J, Koutouzov\u00a0S (2005) IFN\u2011\u03b1 induces early lethal lupus in preautoimmune (new zealand black\u00d7 new zealand white) F1 but not in BALB\/c mice. J\u00a0Immunol 174:2499\u20132506","journal-title":"J Immunol"},{"key":"1760_CR10","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie\u00a0RA, Morand\u00a0EF, Bruce\u00a0IN et\u00a0al (2019) Type\u00a0I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a\u00a0randomised, controlled, phase\u00a03\u00a0trial. Lancet Rheumatol 1:e208\u2013e19","journal-title":"Lancet Rheumatol"},{"key":"1760_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N\u00a0Engl J Med 382:211\u2013221","journal-title":"N Engl J Med"},{"key":"1760_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne\u00a0D, Rovin\u00a0B, Mysler\u00a0EF et\u00a0al (2022) Phase\u00a0II randomised trial of type\u00a0I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 81:496\u2013506","journal-title":"Ann Rheum Dis"},{"key":"1760_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.medcli.2016.02.025","volume":"147","author":"B Hutton","year":"2016","unstructured":"Hutton\u00a0B, Catala-Lopez\u00a0F, Moher\u00a0D (2016) The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA. Med Cl\u00ednica 147:262\u2013266","journal-title":"Med Cl\u00ednica"},{"key":"1760_CR14","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg\u00a0MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725","journal-title":"Arthritis Rheum"},{"key":"1760_CR15","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri\u00a0M, Orbai\u00a0AM, Alarc\u00f3n\u00a0GS et\u00a0al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677\u20132686","journal-title":"Arthritis Rheum"},{"key":"1760_CR16","first-page":"1143","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie\u00a0RA, Petri\u00a0MA, Wallace\u00a0DJ et\u00a0al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Care Res Off J Am Coll Rheumatol 61:1143\u20131151","journal-title":"Arthritis Care Res Off J Am Coll Rheumatol"},{"key":"1760_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","volume":"73","author":"DJ Wallace","year":"2014","unstructured":"Wallace\u00a0DJ, Kalunian\u00a0K, Petri\u00a0MA et\u00a0al (2014) Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: results from EMBLEM, a\u00a0phase\u00a0IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73:183\u2013190","journal-title":"Ann Rheum Dis"},{"key":"1760_CR18","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri\u00a0M, Kim\u00a0MY, Kalunian\u00a0KC et\u00a0al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N\u00a0Engl J Med 353:2550\u20132558","journal-title":"N Engl J Med"},{"key":"1760_CR19","first-page":"205","volume-title":"Assessing risk of bias in a\u00a0randomized trial. Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins\u00a0JP, Savovi\u0107\u00a0J, Page\u00a0MJ, Elbers\u00a0RG, Sterne\u00a0JA (2019) Assessing risk of bias in a\u00a0randomized trial. Cochrane handbook for systematic reviews of interventions, pp\u00a0205\u2013228"},{"key":"1760_CR20","first-page":"447","volume":"86","author":"E Hay","year":"1993","unstructured":"Hay\u00a0E, Bacon\u00a0P, Gordon\u00a0C et\u00a0al (1993) The BILAG index: a\u00a0reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJM: Int J Med 86:447\u2013458","journal-title":"QJM: Int J Med"},{"key":"1760_CR21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/kisup.2012.9","volume":"2","author":"DC Cattran","year":"2012","unstructured":"Cattran\u00a0DC, Feehally\u00a0J, Cook\u00a0HT et\u00a0al (2012) Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139\u2013274","journal-title":"Kidney Int Suppl"},{"key":"1760_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher\u00a0HC, Guyatt\u00a0GH, Griffith\u00a0LE, Walter\u00a0SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J\u00a0Clin Epidemiol 50:683\u2013691","journal-title":"J Clin Epidemiol"},{"key":"1760_CR23","doi-asserted-by":"crossref","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a\u00a0meta-analysis with R: a\u00a0practical tutorial. BMJ Ment Health 22:","DOI":"10.1136\/ebmental-2019-300117"},{"key":"1760_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4078\/jrd.2024.0095","volume":"32","author":"YH Lee","year":"2025","unstructured":"Lee\u00a0YH, Song\u00a0GG (2025) Associations between circulating interleukin-18\u00a0levels and adult-onset still\u2019s disease: a\u00a0meta-analysis. J\u00a0Rheum Dis 32:48\u201356","journal-title":"J Rheum Dis"},{"key":"1760_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4078\/jrd.2023.0059","volume":"31","author":"P Waitayangkoon","year":"2024","unstructured":"Waitayangkoon\u00a0P, Leesutipornchai\u00a0T, Techasatian\u00a0W et\u00a0al (2024) Urate-lowering therapy is associated with a\u00a0reduced risk of arrhythmias: a\u00a0systematic review and meta-analysis. J\u00a0Rheum Dis 31:108\u2013115","journal-title":"J Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01760-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01760-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01760-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:39:14Z","timestamp":1777376354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01760-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1760"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01760-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}